IL18 and nephritis: Intraperitoneal administration of recombinant IL-18 has been shown to exacerbate nephropathy, whereas anti-IL-18 antibodies and IL-18 cDNA vaccines suppress IL-18 in vivo, thereby attenuating lymphocyte proliferation and nephritis (12).